Similar companies
Income Statement (DKK)
| Q4 '23 | QoQ | |
|---|---|---|
| Revenue | 65.9B | 12.1% |
| Gross Profit | 55.8B | 13.9% |
| Cost of Revenue | 10B | 3.1% |
| Operating expense | 29.1B | 31.6% |
| Net Income | 22B | 2.3% |
| EBITDA | 28.5B | 13% |
Balance Sheet (DKK)
| Q4 '23 | QoQ | |
|---|---|---|
| Total Assets | 314B | 4.8% |
| Total Liabilities | 208B | 0.4% |
| Total Equity | 107B | 14.6% |
| Shares Outstanding | 4.48B | 0.3% |
Cash Flow (DKK)
| Q4 '23 | QoQ | |
|---|---|---|
| Cash from operations | 9.55B | 76.7% |
| Cash from financing | -10.1B | 49% |
Financial Highlights for Novo Nordisk in Q4 '23
Novo Nordisk reported a revenue of 65.9B, which is a 12.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 55.8B, marking a 13.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 10B, a 3.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 29.1B, showing a 31.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 22B, showing a -2.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 28.5B, showing a -13% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Novo Nordisk faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.